Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: A liquid pharmaceutical suspension for oral administration containing a bismuth-containing pharmaceutical agent, a suspension system, and water. The suspension system can contain from about 0.001% to about 0.2% gellan gum and from about 0.001% to about 0.75% magnesium aluminum silicate.

Abstract: A method of producing a liquid pharmaceutical suspension by mixing magnesium aluminum silicate, gellan gum, bismuth subsalicylate, and methyl cellulose.

Abstract: This invention relates to compositions comprising hydrophobically modified cationic polymers as well as processes of making and using such compositions. Such hydrophobically modified cationic polymers may be added to the composition in a variety of ways including, but not limited to, as a component of a particle. Advantages of such compositions include the ability to selectively increase the deposition of benefit agents without effectively increasing deposition of undesired materials.

Abstract: A paint containing a surfactant system capable of structuring a non-aqueous liquid composition, wherein the surfactant system comprises at least about 5% of a structuring particle. The surfactant system preferably further comprises a surfactant selected from the group consisting of anionic, nonionic, cationic, amphoteric surfactants and mixtures thereof. A well dispersed mixture of a non-aqueous liquid, for example, a nonionic surfactant, and at least about 25%, by weight of the surfactant system results in the mixture having a yield of at least about 2.0 Pa when measured at 20 sec−1 and 25° C. Moreover, the surfactant system should exhibit a peak when measured by SAXS x-ray diffraction, wherein the peak's center is between about the 1.5 to 2.5 v positions on the 2 theta axis. The structuring particles are most preferably structuring particles of sulfate and linear alkyl benzene sulfonate.

Abstract: A surfactant system capable of structuring a non-aqueous liquid composition, wherein the surfactant system comprises at least about 5% of a structuring particle. The surfactant system preferably further comprises a surfactant selected from the group consisting of anionic, nonionic, cationic, amphoteric surfactants and mixtures thereof. A well dispersed mixture of a non-aqueous liquid, for example, a nonionic surfactant, and at least about 25%, by weight of the surfactant system results in the mixture having a yield of at least about 2.0 Pa when measured at 20 sec−1 and 25° C. Moreover, the surfactant system should exhibit a peak when measured by SAXS x-ray diffraction, wherein the peak's center is between about the 1.5 to 2.5 v positions on the 2 theta axis. The structuring particles are most preferably structuring particles of sulfate and linear alkyl benzene sulfonate. Also provide is a method of making the structuring particle.